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Abstract 
The noncommunicable diseases (NCDs) emergency health kit was developed in response to the growing prevalence of 
NCDs in low and middle-income countries. Under conditions of conflict or following natural disasters, regular treatment 
of this category of diseases is often disrupted and rarely prioritized. This leads to greater morbidity and mortality both in 
the short and long term. The Eastern Mediterranean Region (EMR) has both a high incidence of NCDs and currently is the 
site of several major conflicts and hosts most of the world’s refugees. Therefore, the WHO Regional Office for the Eastern 
Mediterranean initiated the development of the NCD emergency health kit to provide a structured set of medications, 
equipment and renewables to supply the needs of a population of 10 000 people over a period of 3 months following 
disruption of normal medical services. This report discusses the rationale and anticipated use of the NCD emergency 
health kit followed by the selection criteria, structure, content and quantification process of the kit. Finally, the next steps 
are examined, including the procurement, logistics and monitoring and evaluation process of the kit.
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Introduction
Since 1984, the WHO emergency health kit, which 
evolved to become the Interagency Emergency Health 
Kit (IEHK), has provided relief for the health needs of 
populations in crisis (1). The intention of the kit was 
to temporarily provide the essential medications and 
supplies for a population of 10 000. This would cover a 
3-month period when health infrastructure has been 
disrupted by conflict, or in the immediate aftermath of 
a natural disaster. Through its evolution, the emergency 
health kit has gone through several revisions and modular 
additions including a module for malaria treatment and a 
module for HIV treatment (2). Subsequent kits have been 
developed to serve other health needs of populations, 
such as the surgical kit (3) and the reproductive health kit 
(4).
Despite their utility, these kits have yet to address 
noncommunicable diseases (NCDs) in accordance with 
the shifting burden of diseases worldwide (5). The IEHK 
includes a small amount of NCD medication. However, 
it does not have the capacity to provide either the kind 
of medications needed or a sufficient quantity to treat 
populations that have high prevalence of NCDs, like 
those seen in certain low and middle-income countries 
(LMIC).
Noncommunicable diseases account for 70% of 
all deaths globally and of those deaths over 40% are 
premature, occurring before the age of 70. Despite the 
myth that NCDs are diseases of developed nations, 
82% of those premature deaths occur in LMICs (6). In 
addition, given the scale and impact across the globe, 
the economic implications are significant. In 2011, the 
United Nations General Assembly called a high-level 
meeting to put NCDs on the agenda. The following year, 
the World Health Organization (WHO) produced the 
‘Global Action Plan for the Prevention and Control of 
Noncommunicable Diseases’ as a framework for tackling 
this burden. Among its recommendations is Article 
49, which states the deployment of “an interagency 
emergency health kit for treatment of noncommunicable 
diseases in humanitarian disasters and emergencies” (7).
The WHO Regional Office for the Eastern 
Mediterranean (WHO/EMRO) has taken the initiative to 
create an NCD emergency health kit to complement the 
IEHK for several reasons. First, the Eastern Mediterranean 
Region (EMR) has one of the highest prevalence of NCDs 
worldwide. With an adult hypertension prevalence 
ranging from 20 to 30% (8) and diabetes prevalence of 
14% (9), NCDs are one of the greatest health burdens in 
the Region. Second, the EMR hosts the majority of the 
world’s current refugees and internally displaced persons 
(IDPs) (10,11). With numerous countries in emergencies 
and many others hosting refugees, the Region would 
benefit most from an NCD emergency health kit.
The purpose of this report is to present and share the 
development process of the NCD emergency health kit. 
The report is divided into three sections: 1) it describes the 
rationale, purpose and anticipated use of the NCD kit; 2) 
it presents the structure, selection criteria, contents and 
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quantification process of the kit; and 3) it discusses the 
way forward, including the procurement, logistics, and 
monitoring and evaluation process of the kit at selected 
pilot sites.
Rationale and purpose of the NCD kit
In accordance with the minimum standards of the 
Sphere guidelines, the kit is built around several priority 
actions. First, it aims to provide the ongoing medication 
requirements of people who are already on treatment, 
in order to reduce the risk of acute exacerbations and 
complications that lead to morbidity and mortality. 
As a caveat, the kit does not support the initiation of 
medications for those that are newly diagnosed as 
outlined in the Sphere guidance notes (12). Second, the kit 
is meant for the primary health care (PHC) level. However, 
in an emergency the capacity to provide various levels of 
care is heavily dependent upon human resources, and 
often that capacity to deliver NCD care is limited among 
humanitarian providers. Anticipating these difficulties, 
the NCD emergency health kit serves a variety of health 
care settings. The kit can be deployed in various locations 
such a mobile health clinic, primary health centre, field 
hospital, or if necessary in a tertiary hospital.
Structure of the kit
The NCD emergency health kit consists of 5 submodules 
(Table 1). Module 1A (medicines), contains mostly oral 
tablets alongside two different inhalers. Medicines 
requiring cold chain, namely subcutaneous insulin, 
were placed in a separate module (1B), to allow for their 
proper handling. The third module (1C), contains medical 
renewables, such as syringes, lancets and blood and 
urine strips. The final two modules (1D and 1E) contain 
equipment renewables and the equipment itself, selected 
for basic diagnostic ability.
The modularity of the kit was designed to offer 
maximum flexibility, based on country needs and 
capacity. For instance, the exclusion of insulin from the 
medicines submodule into its own cold chain submodule 
was a decision based on logistics and resource uncertainty 
in the field. Emergency situations are unpredictable and 
some situations may not allow for proper refrigeration 
facilities, which in this case, the insulin module 1B may 
be removed from the order. The same idea applies for the 
equipment renewables submodule, since it is assumed 
that the medical equipment module will be ordered 
only once, providing the ability to order separately the 
renewables for those equipment. The first three modules 
are intended to provide sufficient medications and 
renewables for the 3-month initial period.
This modularity allows for flexibility in the uncertain 
climate of emergencies. The kit does not have to be ordered 
as a whole, but may be ordered by submodules depending 
on the needs of the field. The assumption would be that 
after the first order of the full kit, subsequent orders may 
include only the medications and renewables, excluding 
other longer lasting or less utilized submodules.
Content of the kit and selection criteria
The selection criteria of medicines involved several steps. 
First, it was important that all medicines are congruent 
with the WHO Essential Medicines List (13), guidelines 
from the ‘Package of Essential Noncommunicable (PEN) 
Disease Interventions for Primary Health Care in Low-
Resource Settings’ (14), and the Mental Health Gap Action 
Programme (mhGAP) (15). This allows for a standardized 
evidence-based kit with known reliability. Following this 
process was a review of previous emergency health kits 
for the treatment of NCDs such as the Balkan kit, the NCD 
kit utilized in Ukraine, and the mini emergency health 
kit utilized in Pakistan. Finally, soliciting comments 
from the field in emergency countries was important 
in understanding the experience on the ground with 
regards to NCDs. An extensive literature review and a 
regional situational analysis on the provision of NCD 
care to Syrian refugees informed the prioritization of 
diseases to be covered (16).
Following the desk review process on 20 July 2016, 
a multi-agency consultation meeting involving field 
and technical experts of various disciplines was hosted 
by WHO/EMRO in Cairo, Egypt. A discussion weighing 
existing literature, population needs, and practical field 
experience was carried out. This process resulted in the 
finalization of the list of medications and equipment to 
be included in the kit. Also discussed in the meeting were 
the next steps, including the process of procurement, 
field testing, logistics, and monitoring and evaluation 
(M&E).
This emergency kit is designed to treat the major 
NCDs, namely hypertension and cardiac conditions, 







Module (1A): Medicines only, without cold chain insulin 235 120 x 80 x 120 1.920
Module (1B): Medicines cold (insulin) 10 120 x 80 x 80 0.768
Module (1C): Medical renewables 21.8 60 x 40 x 42 0.1008
Module (1D): Equipment supplies 141 120 x 80 x 87 0.8352
Module (1E): Equipment 8.6 60 x 40 x 27 0.0648
Total 416.4 3.689
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diabetes, chronic respiratory diseases, and a selected set 
of mental health and neurological diseases (Figure 1). 
Certain disorders such as cancers, autoimmune disorders 
and end-stage renal diseases require complex diagnostic 
infrastructures, expensive specialized care, and have 
treatment regimens with narrow therapeutic windows. 
These could result in adverse side effects not amenable 
to disrupted health systems. Excluding these conditions, 
the kit covers the essential NCD health care needs of a 
population with a focus on the primary health care level.
As a response to the demand for palliative care 
in emergencies, the kit’s original intention was to 
include medications for both pain and non-pain related 
symptomatic relief, with guidance from WHO’s technical 
report on the ‘Selection and Use of Essential Medicines’ 
(17). However, with consultations from experts and 
practitioners, the ultimate decision was made to exclude 
these medications. This was due to tensions related to 
regulatory restrictions and transportation impediments 
across different Member States, plus possible unintended 
consequences of controlled medications in a climate 
of uncertain security. This point illustrates the various 
dilemmas encountered in the design and selection of 
medicines included in the kit.
Reduction of overlap between the NCD kit and 
the IEHK was crucial to prevent redundant surplus of 
supplies in the field. For this reason, medications for 
eclampsia in pregnancy such as methyldopa, hydralazine 
and magnesium sulfate, were removed. Although the 
NCD kit serves to complement the IEHK, it was important 
for it to have stand-alone capacity and not be completely 
dependent on supplies included in other kits. Thus, the 
inclusion of basic equipment such as sterile gloves, 
stethoscopes, sphygmomanometers and thermometers 
was strategic.
Quantification of drug requirements
The quantification of medications was based on a 
combination of known data and general trends. Data 
from WHO’s NCD country profiles in the EMR were 
utilized to extrapolate regional prevalence and incidence 
of conditions (18). Upon further evaluation was the 
assumption regarding coverage trends, meaning the 
percentage of patients who are on treatment for a certain 
disease. For instance, at a given prevalence of diabetes 
there was an assumption based on trends that about 
50% of patients were on pharmacologic therapy. Further 
assumptions were made for patients on treatment, for 
which the percentage of patients on insulin therapy 
was about 20% (19). The same process was calculated 
for hypertension data (20) with trends regarding 
the percentage of patients who are on monotherapy 
versus dual-therapy regimens (8). After prevalence and 
coverage calculations, the number of physical tablets 
needed was based on the WHO essential medicines 
list (EML) formulary to assess dosages and frequency 
of consumption (13). For medical equipment, further 
considerations were needed. Consumables such as 
glucose strips and syringes were based on prevalence data 
as mentioned above. Other devices such as glucometers, 
sphygmomanometers and stethoscopes were based on 
the number of health care professionals at facilities as 
well. Spare parts and consumables attached to devices 
were also calculated considering the lifespan of the 
devices.
Figure 1 NCD emergency health kit contents organized by disease area
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Next steps
Procurement, logistics, monitoring and 
evaluation
The procurement process of the NCD kit was made 
through international competitive bidding. Technical 
specifications for all items were incorporated in the 
call for proposals to international suppliers. The review 
of suppliers’ proposals involved a multidisciplinary 
team including physicians, pharmacists and biomedical 
engineers. All proposed items were evaluated against the 
following selection: 1) quality of the drugs; 2) compliance 
with the technical specifications for medical devices; 3) 
certifications and quality/safety assurance for medical 
devices; 4) drug packaging (e.g. blister versus jars); 5) total 
price of the kit (not module based); 6) Lead-time for the 
supplier to deliver the first set of kits; and 7) weight and 
volume.
For example, the consideration of drug packaging in 
jars versus blister packs were discussed, since packaging 
may not only affect the end prescriber and user but may 
also alter the weight and volume of the kit, thus having 
an effect on the cost and transportation. Additional 
considerations for devices include voltage and socket 
congruency and language specifications for instructions 
depending on the receiving country. Suppliers identified 
manufacturers globally and obtained price estimates. As 
part of the quality control process, WHO ensured that 
suggested manufacturers were certified by regulatory 
authorities and/or show adherence to WHO Good 
Manufacturing Practices. After selecting one supplier, 
WHO made a visit to the site of production to check 
all items included in the kit. Current cost estimates for 
a full kit providing for 10 000 people over a period of 3 
months range from US$ 13000 to US$ 15000. According to 
the supplier, first production of kits took approximately 
3 months to assemble. However, supplies are planned to 
be stocked by the supplier in order to guarantee rapid 
shipment within 48 hours.
Piloting sites and logistics
Following the selection of a supplier, discussions took 
place on where to first deploy the kits. The criteria for 
selecting pilot sites for NCD kit deployment was the 
following:
1. countries with high NCD burden/caseload based on 
reporting by partners and minimum catchment pop-
ulation of 10 000 people
2. NCD medicines shortage/supply chain disruption
3. minimum technical capacity to deliver NCD medi-
cines
4. cold chain structure/equipment availability
5. capacity to provide basic feedback on kit use (moni-
toring and evaluation activities).
Based on these criteria, a choice was made to start 
implementation of the kit in several sites across Iraq and 
the Syrian Arab Republic. The first set of kits reached 
the north of the Syrian Arab Republic in October 2017. In 
order to set the baseline for sites’ selection and to start 
gathering information for deployment plan development, 
a comprehensive questionnaire has been sent to each of 
the selected sites. This involved finalizing the quantity 
of orders, producing a distribution plans for each site, 
and foreseeing any obstructions. The number of kits to 
be ordered required an estimate of the catchment area 
population served by each health facility. In addition, the 
number of kit modules orders was tailored to the size of 
the population and patient volume to be served. Given the 
nature of conflict and insecurity, an additional number of 
kits were ordered as a buffer stock to ensure continuity of 
care as unpredictable patency of humanitarian corridors 
could impede delivery. Movements across borders 
depend on the export and import country; further steps 
were necessary including registration of suppliers within 
the import country, certification of medications, and 
proper documentation for cross border activities.
Monitoring and evaluation
Following up on the NCD kit’s usage is an integral 
process. By obtaining proper feedback and data, critical 
information will be obtained on whether the kit content 
and quantities served the needs of the population as 
originally intended. Particularly after the first launch 
of the kit, proper data collection and analysis will be 
essential to guide future revisions. This process will not 
only inform the production of a more cost-effective kit, 
but more importantly create a kit that can best serve 
populations in emergencies.
For that purpose, a monitoring and evaluation 
framework was designed that follows the journey of 
the kit from the supplier to end-user. Monitoring and 
Evaluation (M&E) activities were divided into 3 phases: 
1) a pre-deployment phase; 2) a mid-term monitoring 
phase; and 3) an end-term evaluation phase. Survey 
questionnaires were developed and connections with 
first-line service providers were set up to get regular 
feedbacks. Anticipating that insecurity would hamper 
the ability to perform direct visits to implementing 
sites, an electronic platform and mobile applications 
were set up to allow remote monitoring of the kit 
deployment and use. Consisting of a comprehensive 
suite of tools, the electronic platform would allow for the 
remote administration of surveys, export of data, and 
visualization of results. The M&E timeline and type of 
data collected during the various implementation phases 
are outlined in Table 2.
Discussion
“Health system resilience can be defined as the capacity 
of health actors, institutions, and populations to prepare 
for and effectively respond to crises; maintain core 
functions when a crisis hits; and, informed by lessons 
learned during the crisis, reorganize if conditions require 
it” (21).
During emergencies, lives are lost primarily to the 
effect of the environment, communicable diseases 
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and trauma. Humanitarian objectives aim to reduce 
as many of these excess deaths as possible. However, it 
is important to address not only the new diseases but 
also the existing health burdens prior to the emergency. 
Noncommunicable diseases, a group of diseases 
that encompass a wide spectrum of pathologies, are 
particularly difficult to address even in a functioning 
health systems. Some of the problems may have been 
addressed, but with others falling by the wayside 
due to limited infrastructure and resources. During 
emergencies when health systems have been disrupted, 
even basic health needs may not be addressed and lead 
to an exacerbation of existing burdens. Inevitably, these 
diseases, traditionally not foreseen by humanitarian 
actors, contribute to significant levels of morbidity, 
disability and mortality.
The need to bridge together the humanitarian 
objectives and development objectives are integral in 
rebuilding health systems. However, the NCD kit was 
not intended to address the multiple disruptions health 
systems face at a time of an emergency. Under the 
framework of the health system’s building blocks, the 
primary purpose of the kit was to respond to supply 
chains disruption, providing a core set of essential 
medical supplies for the management of the most 
common NCD conditions. Focusing on the most common 
NCDs, the kit supports countries in providing continuity 
of care for people already treated for NCD conditions; 
thus, preventing acute exacerbations that would put an 
exponential burden on health systems.
By these means, it is expected that the kit not only 
improves the provision of essential services during 
acute emergency responses, but also paves the way for 
health system recovery. Therefore, it would anticipate the 
restoration of a regular PHC service delivery system with 
a focus on the most cost-effective NCD interventions, as 
recommended by WHO (22). By stockpiling medicines 
during, or even before emergencies, the kit can help 
countries mitigate disruptions in the future. Finally, 
from a funding perspective, in a climate when NCD care 
is on many donors’ agendas, the kit can be an advocacy 
tool to prioritize the most cost-effective interventions 
and to orient donor funding for NCDs in humanitarian 
responses.
Table 2 Monitoring and Evaluation timeline at pilot sites 






When Upon kit arrival and before its use At 3 months of kit arrival At 6 months of kit arrival
Objective - To provide a starting baseline for 
kit use
- To be informed about parallel 
supplies and document storage 
capacity and conditions
- To verify NCD kit has reached its 
final destination
- To follow up kit use in 
particular in term of content and 
quantification against ordered 
numbers of complete kits/
submodules
- To review NCD kit structure, content 
and quantities adequacy to field needs 
against pre-existing readiness and 
estimated needs
Areas covered by 
monitoring and 
evaluation
- Contextual analysis (emergency, 
service delivery readiness relevant 
to NCD management)
- Baseline assessment (drugs 
stocks, storage capacity, cold chain)
- Kit inspection upon reception
- Relevance of kit content to daily 
practice
- Early stock-outs or non-used 
items
- Relevance of kit content for the 
management of most common NCDs
- Relevance of drug quantities to 
estimated population coverage
- Relevance of kit modularity and drug 
packaging
- Relevance of supportive documentation 
(drug formulary, standards treatment 
guidelines) to local practice
Methods E-survey Follow up calls to piloting sites E-survey
Focal points to 
collect data
pharmacists/logisticians Medical officer or third party 
in charge of the supervision of 
primary health care facility
Medical officer or third party in charge 
of the supervision of primary health care 
facility
Funding: None.
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Report
97
EMHJ – Vol. 24 No. 1 – 2018
ةيراسلا يرغ ضارملأل ةئراطلا ةيحصلا تامزلتسلما ةدع ميمصت
لياسرجوه زناه ،شورلا فيوص ،وينارأ وشتيروم ،لي ناثانوج ،ةملاس ميلس
ةصلالخا
 .طسوتلماو ضفخنلما لخدلا تاذ نادلبلا في ضارملأا هذه راشتنا ديازت ةهجاولم ةيراسلا يرغ ضارملأل ةئراطلا ةيحصلا تامزلتسلما ةدع تم ِّمص
 يدؤيو .ةيولولأا ىطعُي مالقو عاطقنلال ضارملأا نم ةئفلا هذله مظتنلما جلاعلا ضرعتي ام ًابلاغ ،ةيعيبطلا ثراوكلا باقعأ في وأ عاصرلا تلااح يفف
 ضارملأاب ةباصلإا تلادعم عافتراب طسوتلما قشر ميلقإ مستيو .كلذك ديعبلا ىدلما لىعو ةداح ةروصب تايفولاو ةضارلما تلادعم ةدايز لىإ كلذ
 ةحصلا ةمظنم بتكم ثدحتسا ،كلذ لىعو .لماعلا يئجلا مظعلم ىوأمو ىبرك تاعاصر ةدعل ًاحسرم ليالحا تقولا في حبصأو لب ةيراسلا يرغ
 تامزلتسلماو ةزهجلأاو ةيودلأا نم ةلكيهم ةعوممج يرفوت ةيغب ةيراسلا يرغ ضارملأل ةئراطلا ةيحصلا تامزلتسلما ةدع طسوتلما قشر ميلقلإ ةيلماعلا
 يقطنلما  ساسلأا  ريرقتلا  اذه  شقانيو  .مهنع  ةداتعلما  ةيبطلا  تامدلخا  عاطقنا  بقع  رهشأ  3  ةترفل  صخش  10 000  تاجايتحا  ةيبلتل  ةددجتلما
 اهاوتمحو  اهتيلكيهو  اهرايتخا  يرياعم  لوانتي  اهدعبو  ،اله  ىخوتلما  لماعتسلااو  ةيراسلا  يرغ  ضارملأل  ةئراطلا  ةيحصلا  تامزلتسلما  ةدع  ميمصتل
 ةصالخا مييقتلاو دصرلا ةيلمعو ةيتسجوللا روملأاو ءاشرلا ةيلمع كلذ في ماب ،ةلبقلما تاوطلخا في ريرقتلا رظني ،ًايرخأو .اله يمكلا ديدحتلا ةيلمعو
.تامزلتسلما ةعومجمب
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Élaboration d’un kit sanitaire d’urgence pour les maladies non transmissibles
Résumé
Le kit sanitaire d’urgence pour les maladies non transmissibles (MNT) a été mis au point en réponse à l’augmentation 
de la prévalence des MNT dans les pays à revenu faible et intermédiaire. Dans les situations de conflit ou à la suite de 
catastrophes naturelles, les traitements réguliers pour cette catégorie de maladies sont souvent interrompus et la priorité 
leur est rarement donnée. Ceci conduit à une morbidité et une mortalité plus élevées, tant sur le court terme que sur le long 
terme. Non seulement la Région de la Méditerranée orientale affiche une incidence élevée pour les MNT, mais elle est 
aussi actuellement le lieu de plusieurs conflits de grande ampleur et accueille la plus importante population de réfugiés 
au monde. Pour cette raison, le Bureau régional de l’OMS pour la Méditerranée orientale a amorcé l’élaboration d’un kit 
sanitaire d’urgence pour les MNT afin de fournir un ensemble structuré de médicaments, de matériel et de fournitures 
renouvelables permettant de répondre aux besoins de 10 000 personnes sur une période de trois mois après l’interruption 
des services médicaux normaux . Le présent rapport examine les raisons de l’élaboration d’un kit sanitaire d’urgence pour 
les MNT et la façon dont il pourra être utilisé, ainsi que les critères de sélection, sa structure, son contenu et ses processus 
de quantification. Enfin, les dernières étapes sont examinées, notamment l’achat, les aspects logistiques et les processus 
de suivi et d’évaluation du kit. 
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